All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What’s new in mantle cell lymphoma?

During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Martin Dreyling, Ludwig-Maximilians-Universität München, Munich, DE. We asked, What’s new in mantle cell lymphoma?

What’s new in mantle cell lymphoma?

In this video, Dreyling discusses the results of trials on rituximab maintenance and the standard approach in first relapse, such as ibrutinib, BTK inhibitors, and the combination of ibrutinib and bosutinib. To conclude, Dreyling outlines a comparison of chimeric antigen receptor (CAR) T-cell therapy and conventional therapies.

 

Share: